Diversified Healthcare Trust (DHC) Beta: Monthly Comparison and Analysis

Diversified Healthcare Trust (NASDAQ: DHC) closed the day trading at $2.99 down -3.24% from the previous closing price of $3.09. In other words, the price has decreased by -$0.1000 from its previous closing price. On the day, 1004004 shares were traded.

Ratios:

For a better understanding of DHC, let’s look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 1.22 whereas as Long-Term Debt/Eq ratio is at 1.21.

Wells Fargo Downgraded its Overweight to Equal Weight on January 17, 2020, while the target price for the stock was maintained at $9.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 14 when PORTNOY ADAM D. bought 2,000,000 shares for $3.07 per share. The transaction valued at 6,132,600 led to the insider holds 23,250,019 shares of the business.

PORTNOY ADAM D. bought 1,992,259 shares of DHC for $6,026,783 on Jun 13. The Director now owns 21,250,019 shares after completing the transaction at $3.03 per share. On Jun 12, another insider, PORTNOY ADAM D., who serves as the Director of the company, bought 2,011,256 shares for $2.87 each. As a result, the insider paid 5,778,540 and bolstered with 19,257,760 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DHC now has a Market Capitalization of 716.45M and an Enterprise Value of 3.29B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.28 while its Price-to-Book (P/B) ratio in mrq is 0.31. Its current Enterprise Value per Revenue stands at 2.33 whereas that against EBITDA is 16.18.

Stock Price History:

Over the past 52 weeks, DHC has reached a high of $3.96, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 3.0796, while the 200-Day Moving Average is calculated to be 2.4719.

Shares Statistics:

Over the past 3-months, DHC traded about 1.48M shares per day on average, while over the past 10 days, DHC traded about 1.3M shares per day. A total of 240.42M shares are outstanding, with a floating share count of 215.61M. Insiders hold about 10.32% of the company’s shares, while institutions hold 76.17% stake in the company. Shares short for DHC as of Feb 15, 2024 were 4.89M with a Short Ratio of 3.30, compared to 4.94M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.03% and a Short% of Float of 2.30%.

Dividends & Splits

DHC’s forward annual dividend rate is 0.04, up from 0.04 a year ago. Against a Trailing Annual Dividend Yield of 1.29%, it implies a Forward Annual Dividend Yield of 1.30%. The stock’s 5-year Average Dividend Yield is 5.35.

Earnings Estimates

Current recommendations for the stock of the company come from 1 analysts. On average, analysts expect EPS of -$0.28 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.28, while EPS last year was -$0.27. The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.27 and low estimates of -$0.27.

Analysts are recommending an EPS of between -$1.05 and -$1.05 for the fiscal current year, implying an average EPS of -$1.05. EPS for the following year is -$0.76, with 1 analysts recommending between -$0.76 and -$0.76.

Revenue Estimates

2 analysts predict $368.71M in revenue for the current quarter. It ranges from a high estimate of $371.42M to a low estimate of $366.01M. As of the current estimate, Diversified Healthcare Trust’s year-ago sales were $337.61M, an estimated increase of 9.20% from the year-ago figure.

A total of 2 analysts have provided revenue estimates for DHC’s current fiscal year. The highest revenue estimate was $1.51B, while the lowest revenue estimate was $1.5B, resulting in an average revenue estimate of $1.5B. In the same quarter a year ago, actual revenue was $1.41B, up 6.70% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $1.59B in the next fiscal year. The high estimate is $1.61B and the low estimate is $1.58B. The average revenue growth estimate for next year is up 6.00% from the average revenue estimate for this year.

Most Popular

[the_ad id="945"]